ALN-TTRsc02: Phase I started

Alnylam began a single-blind, placebo-controlled, U.K. Phase I trial to evaluate single ascending doses of subcutaneous ALN-TTRsc02 in up to 100 healthy volunteers. The Genzyme Corp. unit of Sanofi ...